{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:23Z","timestamp":1787169623336,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Abnormal liver function tests (LFTs) are common in inflammatory bowel disease (IBD), yet data from the Middle East are lacking. We aimed to determine the prevalence, etiological spectrum, and risk factors for abnormal LFTs in a tertiary IBD cohort in the United Arab Emirates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective cohort study with cross-sectional and longitudinal components, all adult IBD patients in a tertiary institutional registry were screened for abnormal LFTs. Etiologies were assigned across predefined categories, and logistic regression identified associated factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Persistent abnormal LFTs (per the operational definition) were identified in 72 of 510 patients (14.1%, 95% CI 11.4\u201317.4%). The most common etiology was metabolic dysfunction-associated steatotic liver disease (MASLD, 22.2%), followed by infection-related causes (11.1%), drug-induced liver injury (11.1%), and IBD activity-related causes (4.2%). Viral hepatitis screening was performed in \u226586% of cases; autoimmune markers were tested in 36\u201356%, and FibroScan in 24%. After adjustment for concomitant primary sclerosing cholangitis (PSC-IBD) as a clinically important confounder, cumulative advanced therapy exposure remained associated with abnormal LFTs (adjusted OR 1.20, 95% CI 1.00\u20131.42,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041); PSC-IBD itself was strongly associated with abnormal LFTs in the model (adjusted OR 8.69, 95% CI 3.11\u201325.24,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), as expected. LFTs normalized in 30.0% and improved in 20.0% of patients during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Abnormal LFTs affected one in seven IBD patients in this UAE cohort, with MASLD as the leading cause. These findings suggest potential value in integrating structured liver investigation algorithms into routine IBD care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_131_26","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:00:09Z","timestamp":1780462809000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and etiology of abnormal liver function tests in a tertiary inflammatory bowel disease cohort in the United Arab Emirates: A cross-sectional study"],"prefix":"10.4103","author":[{"given":"Heba","family":"Abualkas","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitha","family":"Al Hosani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Rifai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed N.","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom"},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"R1-20260603","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1572-0241.2006.00947.x","article-title":"Abnormal hepatic biochemistries in patients with inflammatory bowel disease","volume":"102","author":"Mendes","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R2-20260603","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.35.1.84","article-title":"Liver disease in ulcerative colitis: An epidemiological and follow up study in the county of Stockholm","volume":"35","author":"Broom\u00e9","year":"1994","journal-title":"Gut"},{"key":"R3-20260603","doi-asserted-by":"crossref","DOI":"10.4137\/CGast.S13125","article-title":"Liver function test abnormalities in patients with inflammatory bowel diseases: A hospital-based survey","volume":"7","author":"Cappello","year":"2014","journal-title":"Clin Med Insights Gastroenterol"},{"key":"R4-20260603","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/ecco-jcc\/jjad157","article-title":"Prevalence of hepatobiliary manifestations in inflammatory bowel disease: A GRADE assessed systematic review and meta-analysis of more than 1.7 million patients","volume":"18","author":"Beheshti Maal","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R5-20260603","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ibd.20160","article-title":"Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R6-20260603","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12794","article-title":"Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease","volume":"40","author":"Gizard","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-20260603","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/liv.13265","article-title":"Hepatic manifestations of inflammatory bowel diseases","volume":"37","author":"Restellini","year":"2017","journal-title":"Liver Int"},{"key":"R8-20260603","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R9-20260603","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241311165","article-title":"Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: An umbrella review of meta-analyses","volume":"18","author":"Hong","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"R10-20260603","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4254\/wjh.v14.i2.319","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: A practical approach","volume":"14","author":"N\u00fa\u00f1ez","year":"2022","journal-title":"World J Hepatol"},{"key":"R11-20260603","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4254\/wjh.v13.i12.1828","article-title":"Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders","volume":"13","author":"Mazza","year":"2021","journal-title":"World J Hepatol"},{"key":"R12-20260603","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-20260603","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: Epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"25","author":"Zou","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R14-20260603","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"7","author":"Sourianarayanane","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R15-20260603","first-page":"1","article-title":"Glucocorticosteroids and the risk of NAFLD in inflammatory bowel disease","author":"Jarmakiewicz-Czaja","year":"2022","journal-title":"Can J Gastroenterol Hepatol 2022"},{"key":"R16-20260603","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"R17-20260603","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"R18-20260603","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/apt.13159","article-title":"New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease","volume":"41","author":"Shelton","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-20260603","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MCG.0000000000001084","article-title":"Hepatotoxicity of inflammatory bowel disease medications","volume":"52","author":"Shamberg","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"R20-20260603","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R21-20260603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R22-20260603","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/flgastro-2024-102781","article-title":"Investigation of abnormal liver blood tests in patients with inflammatory bowel disease","volume":"15","author":"Scott","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"R23-20260603","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R24-20260603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000518003","article-title":"Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: A systematic review and meta-analysis","volume":"6","author":"Mosli","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"R25-20260603","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int"},{"key":"R26-20260603","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R27-20260603","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"key":"R28-20260603","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15537\/smj.2025.46.1.20240758","article-title":"Hepatobiliary manifestations of inflammatory bowel disease in Saudi Arabia: A retrospective analysis","volume":"46","author":"Aljiffry","year":"2025","journal-title":"Saudi Med J"},{"key":"R29-20260603","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"key":"R30-20260603","doi-asserted-by":"crossref","first-page":"749.1","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R31-20260603","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"R32-20260603","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"R34-20260603","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/jgh3.12831","article-title":"Inflammatory bowel disease type influences development of elevated liver enzymes","volume":"6","author":"Cheng","year":"2022","journal-title":"JGH Open"},{"key":"R35-20260603","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MEG.0000000000000350","article-title":"Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment","volume":"27","author":"Schr\u00f6der","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R36-20260603","doi-asserted-by":"crossref","first-page":"101002","DOI":"10.1016\/j.lanepe.2024.101002","article-title":"Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015\u20132027): A nationwide, population-based study","volume":"44","author":"Crothers","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"R37-20260603","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1572-0241.2007.01187.x","article-title":"Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review","volume":"102","author":"Gisbert","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R38-20260603","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R39-20260603","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: Final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R40-20260603","first-page":"162","article-title":"Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: The IDLE study","volume":"33","author":"Worland","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"R41-20260603","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.crohns.2013.12.006","article-title":"Detection of liver injury in IBD using transient elastography","volume":"8","author":"Thin","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R42-20260603","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00384-021-04065-8","article-title":"Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up","volume":"37","author":"Van Lingen","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"R43-20260603","first-page":"54","article-title":"Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: A retrospective single-center study","volume":"36","author":"Dias","year":"2023","journal-title":"Ann Gastroenterol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_131_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:09:05Z","timestamp":1787166545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_131_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":42,"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_131_26","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2026-03-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}